Indaptus Therapeutics Company Insiders
| INDP Stock | USD 1.70 -0.06 -3.41% |
Indaptus Therapeutics employs about 7 people. The company is managed by 8 executives with a total tenure of roughly 17 years. There are nearly 0.88 employees per reported executive. A leadership review of Indaptus Therapeutics matters because management quality often shapes how effectively strategy is translated into revenue growth, margins, and cash generation. This section is most valuable when leadership behavior is connected with profitability trends, balance-sheet quality, and the resilience of the business model.
Indaptus | Build portfolio with Indaptus Stock |
Management Team Effectiveness
The company has return on total asset (ROA) of -148.91 % which suggests that the asset base is not productive at current operating levels. This is extremely low compared to the sector. Similarly, it shows a return on stockholder's equity (ROE) of -587.59 %, which implies that returns to shareholders were negative during the period.Insider Trading Activities
Tracking Indaptus Therapeutics' insider filings adds context. Executives often respond to business conditions well before market sentiment shifts. Most U.S. insider trades appear in Form 4 filings. The value comes from reading the sequence, not one filing in isolation.
Indaptus Therapeutics carries a considerable amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. The ownership breakdown for Indaptus Therapeutics shows approximately 4% institutional, 37% insider, and 59% public.
Holders Distribution
Institutional investors in Indaptus Therapeutics typically operate with more research capacity, technology, and trading scale than retail holders, which is why their activity can materially affect price behavior. Used correctly, the ownership map shows where professional sponsorship may be strong and where exit risk could still be significant.
Workforce Comparison
Indaptus Therapeutics is rated below average for number of employees against industry peers. The total workforce of Health Care industry is currently estimated at about 126. Indaptus Therapeutics holds roughly 7.0 in number of employees claiming about 6% of equities under Health Care sector.
Insider Trading History
Indaptus Therapeutics' insider log provides a timeline of management conviction alongside earnings and guidance changes. Shares outstanding are near 2.2 M. Since insider trades are publicly filed, the record helps verify whether management actions match their words.
Notable Stakeholders
An Indaptus Therapeutics stakeholder is any individual or group with an interest in the outcome of the business, which is why stakeholder analysis can reveal who may influence strategy and oversight. Indaptus Therapeutics' stakeholders can support or challenge the entity's direction, which is why tracking them can add context around price-sensitive developments.
| Jeffrey JD | CoCEO Director | Profile | |
| David Lazar | Chairman CoCEO | Profile | |
| Nir Sassi | Secretary CFO | Profile | |
| MD MBA | Chief Officer | Profile | |
| Jeffrey Meckler | CEO Director | Profile | |
| Walt Esq | Chief Officer | Profile | |
| Michael Newman | Chief Founder | Profile | |
| Boyan MD | Chief Officer | Profile |
Management Information & Data Sources
Indaptus Therapeutics is a micro-cap company. Executive review focuses on insiders, senior management, and employee signals. Leadership stability matters when evaluating execution against stated business priorities. CEO is Jeffrey JD with 7 employees and 8 reported executives.
For Indaptus Therapeutics, this section uses periodic company reporting and market reference feeds with Macroaxis normalization rules applied to keep cross-asset comparisons consistent. Intraday timing differences may exist. Insider and management fields are mapped from published filings and company disclosures.
This content is curated and reviewed by:
Gabriel Shpitalnik - Member of Macroaxis Editorial BoardWorkforce Efficiency and Productivity
Workforce metrics tied to Indaptus Therapeutics offer a useful way to test whether headcount and economic output are moving in a productive direction. The business is commonly classified in the Healthcare sector and the Biotechnology industry.
Indaptus Therapeutics Manpower Efficiency
Return on Indaptus Therapeutics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 3M | |
| Net Loss Per Executive | 2.6M | |
| Working Capital Per Employee | 460.6K | |
| Working Capital Per Executive | 403.1K |
Additional Tools for Indaptus Stock Analysis
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Portfolio Holdings Check your current holdings and cash position to determine if your portfolio needs rebalancing | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |